Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;99(2):E63-E66.
doi: 10.1002/ajh.27180. Epub 2023 Dec 15.

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Omer Karrar  1 , Maymona Abdelmagid  1 , Masooma Rana  1 , Moazah Iftikhar  1 , Kristen McCullough  1 , Aref Al-Kali  1 , Hassan B Alkhateeb  1 , Kebede H Begna  1 , Michelle A Elliott  1 , Abhishek Mangaonkar  1 , Antoine Saliba  1 , Mehrdad Hefazi Torghabeh  1 , Mark R Litzow  1 , William Hogan  1 , Mithun Shah  1 , Mrinal M Patnaik  1 , Animesh Pardanani  1 , Talha Badar  2 , Hemant Murthy  2 , James Foran  2 , Jeanne Palmer  3 , Lisa Sproat  3 , Nandita Khera  3 , Cecilia Arana Yi  3 , Ayalew Tefferi  1 , Naseema Gangat  1
Affiliations
Free article

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Omer Karrar et al. Am J Hematol. 2024 Feb.
Free article

Abstract

Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).

PubMed Disclaimer

References

REFERENCES

    1. Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:502-526.
    1. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.
    1. Gangat N, Karrar O, Iftikhar M, et al. Venetoclax and hypomethylating agent combination therapy in newly-diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2023;99:193-202.
    1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345-1377.
    1. Aiba M, Shigematsu A, Suzuki T, Miyagishima T. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. 2023;102:541-546.

MeSH terms

LinkOut - more resources